Surefire Medical touts infusion tech in liver cancer trial
Surefire Medical touted data today from a retrospective analysis of 85 bridge-to-transplant liver cancer patients treated with transarterial chemoembolization.
The data showed that therapy delivered using the Surefire infusion system yielded an 80% complete response in 1 treatment compared to 52% with a standard endhole microcatheter. The analysis also demonstrated a lower recurrence rate of liver cancer at 1 month for patients that used Surefire’s technology instead of a conventional microcatheter.
Get the full story at our sister site, Drug Delivery Business News.
The post Surefire Medical touts infusion tech in liver cancer trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Surefire Medical Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Liver | Liver Transplant | Transplant Surgery | Transplants | Urology & Nephrology